Nkarta, Inc. (NKTX)
$1.69
Rating:
Recommendation:
-
| Symbol | NKTX |
|---|---|
| Price | $1.69 |
| Beta | -0.050 |
| Volume Avg. | 0.49M |
| Market Cap | 82.908M |
| Shares () | - |
| 52 Week Range | 1.53-14.57 |
| 1y Target Est | - |
| DCF Unlevered | NKTX DCF -> | |
|---|---|---|
| DCF Levered | NKTX LDCF -> | |
| ROE | -34.12% | Strong Sell |
| ROA | -28.55% | Sell |
| Operating Margin | - | |
| Debt / Equity | 28.46% | Neutral |
| P/E | -0.65 | |
| P/B | 0.26 | Neutral |
Latest NKTX news
About
Download (Excel)Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.